Bedrijfsoverzicht
iRhythm Holdings, Inc. is a digital healthcare enterprise focused on the design, development, and commercialization of device-based technologies that deliver ambulatory cardiac monitoring services for the diagnosis of arrhythmias within the United States. The company operates within the healthcare sector, specifically the medical devices industry, where it leverages advanced technology to provide continuous monitoring solutions that aid in identifying irregular heart rhythms outside of a clinical setting. In terms of scale, the entity maintains a market capitalization of $3.72 billion and employs approximately 2,400 individuals across its operations. With annual revenue reaching $747.14 million, these financial metrics indicate that iRhythm Holdings has established itself as a significant player in the specialized cardiac monitoring market, commanding a substantial valuation relative to its sales output and workforce size.
Financiële gezondheid
The company reported total revenue of $747.14 million over the trailing twelve months, yet it posted a net income loss of $44,551,000 and an EBITDA of -$30,568,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and other deductions significantly exceed gross profits, resulting in an overall operating deficit despite high sales volume. However, the company generated positive free cash flow of $71.67 million, which provides essential financial flexibility to fund operations, invest in research, or manage liquidity needs without immediate reliance on external financing. Profitability analysis shows a gross margin of 70.6%, indicating high efficiency in production and sales, while the operating margin stands at 4.2% and the profit margin is negative at -6.0%, reflecting the heavy costs associated with scaling the business and covering administrative expenses. The balance sheet presents a complex picture with cash reserves of $583.76 million against total debt of $731.18 million, resulting in a debt-to-equity ratio of 478.69, which suggests a highly leveraged capital structure where debt obligations far exceed equity. Despite this leverage, the current ratio is a robust 4.63, indicating that the company holds ample current assets to cover its short-term liabilities and maintain strong short-term liquidity. Furthermore, the return on equity is -36.6% and the return on assets is -2.4%, metrics that reveal that management has not yet achieved profitability on the capital invested, signaling a period of reinvestment or operational challenges in generating returns relative to the book value.
Waarderingsbeoordeling
Valuation metrics for iRhythm Holdings present a disparity between historical performance and future expectations, with a trailing P/E ratio that is not available due to current losses, while the forward P/E is quoted at 137.79. This significant difference between the unavailable trailing figure and the high forward P/E implies that the market is pricing in substantial expected earnings growth or a fundamental turnaround in profitability that is not yet reflected in historical data. The price-to-book ratio is 24.37, which indicates that the market is valuing the company at a heavy premium over its tangible book value, suggesting investors are betting on intangible assets, brand strength, or future growth potential rather than current asset backing. Alternative valuation measures show a price-to-sales ratio of 4.98 and an EV/EBITDA of -126.66, which suggest that traditional earnings-based valuation models are less applicable and that the stock is being valued primarily on revenue multiples and growth prospects despite the negative earnings multiple. Regarding price momentum, the stock has traded between a 52-week low of $97.16 and a 52-week high of $212.00, meaning the current market price sits within this historical volatility range but reflects the uncertainty surrounding its earnings trajectory. The beta value is 1.18, which indicates that the stock's price volatility is slightly higher than the broader market, suggesting that the share price is more sensitive to market fluctuations than a standard index stock.
Growth & Income
Revenue growth year-over-year stands at 27.1%, demonstrating strong top-line expansion, whereas earnings growth is not available due to the company's current unprofitability. This divergence implies that the company is prioritizing rapid revenue expansion and market share capture over immediate profit generation, a common strategy in the growth phase of a medical device business where reinvestment costs are high. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders but instead retains earnings to fund operations, debt reduction, or strategic growth initiatives. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion and a complete retention of cash flows to support the company's leveraged balance sheet and operational scaling, rather than providing current income to investors.